In brief
McKinsey & Company has reached a $650 million settlement with the US Department of Justice (DOJ) concerning its involvement in the opioid crisis. The firm was charged with conspiring alongside Purdue Pharma to misbrand prescription drugs, impacting the distribution of OxyContin. In a statement, McKinsey expressed regret over its past actions and acknowledged the harm caused by opioids. The settlement follows a series of legal challenges against McKinsey, which previously settled nearly $1 billion over similar issues. This agreement, part of a deferred prosecution deal, could lead to the dismissal of charges if McKinsey meets referenced reform conditions within five years.
The consulting firm McKinsey & Company has agreed to pay $650 million to settle criminal charges related to its association with Purdue Pharma, the maker of the notorious painkiller OxyContin. The US Department of Justice accused McKinsey of conspiring to misbrand prescription drugs, facilitating undue opioid distribution, and obstructing justice. Documents revealed that McKinsey had provided Purdue with strategies to significantly enhance OxyContin sales. The settlement marks a significant fallout from the ongoing opioid crisis in the US, where opioid abuse has led to soaring addiction and fatal overdoses.Former McKinsey senior partner Martin Elling is expected to plead guilty to obstruction for destroying evidence tied to the case. As part of the deferred prosecution agreement, the charges against McKinsey can be dismissed if the firm implements required reforms over the next five years. McKinsey had already settled for approximately $1 billion concerning its involvement with Purdue and other pharmaceutical entities. Purdue Pharma itself pleaded guilty to similar charges in 2020, agreeing to an $8.3 billion settlement after admitting to facilitating the prescription of drugs without proper medical justification.
